DE3888994D1 - Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen. - Google Patents

Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.

Info

Publication number
DE3888994D1
DE3888994D1 DE3888994T DE3888994T DE3888994D1 DE 3888994 D1 DE3888994 D1 DE 3888994D1 DE 3888994 T DE3888994 T DE 3888994T DE 3888994 T DE3888994 T DE 3888994T DE 3888994 D1 DE3888994 D1 DE 3888994D1
Authority
DE
Germany
Prior art keywords
androst
aza
carbamoyl
beta
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3888994T
Other languages
English (en)
Other versions
DE3888994T2 (de
Inventor
Gary H Rasmusson
Glen F Reynolds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21878727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3888994(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE3888994D1 publication Critical patent/DE3888994D1/de
Application granted granted Critical
Publication of DE3888994T2 publication Critical patent/DE3888994T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE3888994T 1987-04-03 1988-03-30 Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen. Expired - Lifetime DE3888994T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3480687A 1987-04-03 1987-04-03

Publications (2)

Publication Number Publication Date
DE3888994D1 true DE3888994D1 (de) 1994-05-19
DE3888994T2 DE3888994T2 (de) 1994-11-03

Family

ID=21878727

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3888994T Expired - Lifetime DE3888994T2 (de) 1987-04-03 1988-03-30 Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.

Country Status (5)

Country Link
EP (1) EP0285382B1 (de)
CA (1) CA1302277C (de)
CY (1) CY1807A (de)
DE (1) DE3888994T2 (de)
HK (1) HK116494A (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0542802T3 (da) * 1990-08-10 1996-07-22 Upjohn Co Stimulering af hårvækst med kaliumkanalåbnere og 5alfa-reduktase-inhibitorer
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
GB2274060A (en) * 1993-01-07 1994-07-13 Merck & Co Inc Treatment of patterned alopecia with 17ß-acyl-4-aza-5-androst-1-ene-3-ones and minoxidil
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994022900A1 (en) * 1993-04-02 1994-10-13 Ciba-Geigy Ag AZA-ANDROSTANE-17β-CARBOXAMIDES
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
AU700565B2 (en) * 1993-10-15 1999-01-07 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitor formulations
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
RU2142956C1 (ru) 1993-10-21 1999-12-20 Мерк Энд Ко., Инк. 16-замещенные 4-аза-андростаны, соединения, способы ингибирования, фармацевтическая композиция
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
JPH11513380A (ja) * 1995-09-27 1999-11-16 メルク エンド カンパニー インコーポレーテッド ５−αレダクターゼ阻害剤によるアンドロゲン性脱毛症の予防方法
IL124764A0 (en) * 1998-06-04 1999-01-26 Univ Ben Gurion Topical composition for treatment of baldness
DE60313603T2 (de) 2002-04-24 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
PT1644024T (pt) 2003-06-06 2019-10-24 Univ Texas Soluções antimicrobianas de lavagem por infusão.
JP2012504135A (ja) 2008-09-27 2012-02-16 ジャイナ ファーマシューティカルズ，インコーポレーテッド 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions

Also Published As

Publication number Publication date
EP0285382B1 (de) 1994-04-13
EP0285382A2 (de) 1988-10-05
EP0285382A3 (en) 1990-09-12
CA1302277C (en) 1992-06-02
HK116494A (en) 1994-11-04
DE3888994T2 (de) 1994-11-03
CY1807A (en) 1995-09-08

Similar Documents

Publication Publication Date Title
DE68909219D1 (de) Behandlung von obesitas.
DE3888378D1 (de) Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
DE3752141D1 (de) Mittel zur behandlung von neuropathie
DE69019488D1 (de) Behandlung von Geflügel.
DE68920775D1 (de) Behandlung von faserigen Materialien.
DE68907909D1 (de) Praeparat zur behandlung von erektionsstoerungen.
DE3576328D1 (de) Behandlung feuerfester gegenstaende.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE3484439D1 (de) Behandlung von diarrhoee bei tieren.
DE69018043D1 (de) Behandlung von Geflügel.
DE3888994D1 (de) Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
DE3751780D1 (de) Behandlung von Haarausfall
DE68907423D1 (de) Behandlung der akne.
DE3777861D1 (de) Behandlung von gasen.
DE3770184D1 (de) Behandlung von gasstroemen.
DE3670310D1 (de) Elektrochemische behandlung von ligninen.
DE3885913D1 (de) Aufbereitung von Alkoxysilanen.
DE3680881D1 (de) Behandlung von hologrammen.
DE68923219D1 (de) Behandlung von Abfällen.
NO892505L (no) Behandling av vandige dispersjoner.
DE3871010D1 (de) Behandlung von unfruchtbarkeit.
DE68912670D1 (de) Behandlung von Celluloseblättern.
DE3777656D1 (de) Mittel zur behandlung von alopezien.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
DE3751510D1 (de) Düse zur Behandlung von Fäden.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition